Human Holdings Co (2415) Q4 2026 earnings summary

Executive summary

• Revenue/net sales increased 2.2% year-over-year to ¥102,539 million (¥102.5 billion), with all segments posting higher sales.

• Operating income/profit rose 6.1% to ¥3,614 million (¥3.6 billion), and ordinary income/profit grew 8.7% to ¥3,887 million (¥3.9 billion) year-over-year.

• Net income/profit attributable to parent company shareholders declined 15.0% to ¥2,216 million (¥2.2 billion) due to special/extraordinary losses from subsidiary reorganization, impairment, and business withdrawal.

• Comprehensive income for the year was ¥2.2 billion, down from ¥2.6 billion in the prior year.

Financial highlights

• Revenue: ¥102,539 million (+2.2% YoY); Operating income: ¥3,614 million (+6.1% YoY); Ordinary income: ¥3,887 million (+8.7% YoY); Net income: ¥2,216 million (–15.0% YoY).

• Gross profit increased to ¥26.4 billion from ¥25.8 billion year-over-year.

• Earnings per share decreased to ¥213.60 from ¥251.21 year-over-year.

• Special/extraordinary losses of ¥390–390.9 million were recorded for subsidiary reorganization, impairment, and business withdrawal, while the previous year included a ¥140 million special/extraordinary gain from business sales.

• Net assets rose to ¥19.5 billion, with an equity ratio of 37.5% as of March 31, 2026.

Outlook and guidance

• FY2027 revenue/net sales forecast: ¥106,000 million (+3.4% YoY); operating income/profit: ¥3,350 million (–7.3% YoY); ordinary income/profit: ¥3,650 million (–6.1% YoY); net income/profit: ¥2,450 million (+10.5% YoY); EPS forecast at ¥236.08.

• Dividend forecast for FY2027 is ¥71 per share, up ¥2 from the previous year.

• Operating and ordinary income are expected to decline due to higher personnel costs in care and upfront investments in new hospice homes.